Account
Articles
07.09.2023
HUMN legislation – enabler or barrier for advanc...

This article explores the new EU pharmaceutical package and criteria of high unmet medical need (HUM...

Read more
Articles
07.09.2023
Prescription Price Puzzles: The Sky-High Cost of O...

This article explores the significant disparities between the US and Europe regarding orphan drugs a...

Read more
Case Study
26.04.2023
Gaining payer insights

Our client required focused payer value messages for their PUMA product as payers were not recognizi...

Read more
Case Study
26.04.2023
Development of an EU P&R strategy

Our client needed to understand the clinical and economic evidence requirements that drive payer dec...

Read more
Case Study
26.04.2023
Gaining payer insights

Our client required focused payer value messages for their orphan drug as payers were not recognizin...

Read more
Newsletter
30.03.2023
PMA Insights: Week 13 SPECIAL EDITION – Worl...

We summarise the World EPA Congress 2023 including plenary sessions on EU HTA, market archetypes, he...

Read more
Newsletter
15.03.2023
PMA Insights: Week 11

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
07.03.2023
Are acute therapies and curative drugs more afford...

We've prepared an analysis of the top 10 most expensive drugs in the US compared with Germany, in th...

Read more
Newsletter
02.02.2023
PMA Insights: Week 5

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Case Study
01.01.2023
Securing reimbursement for an orphan drug via NICE

Our client was seeking NICE approval for their ultra-orphan drug in an indication that was not well ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.